Jeffrey K Browne

Address:

2169 Gold Poppy St, Brentwood, CA 94513

VIN:

1GNFC13J07R150117

Make:

CHEVROLET

Model:

TAHOE

Year:

2007

US Patent:

7304150, Dec 4, 2007

Filed:

Nov 27, 2000

Appl. No.:

09/723955

Inventors:

Joan C. Egrie - Newbury Park CA, US
Steven G. Elliott - Newbury Park CA, US
Jeffrey K. Browne - Camarillo CA, US
Karen C. Sitney - Studio City CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14/505
C07K 16/46
C07H 21/00

US Classification:

536 2351, 530397, 5303873

Abstract:

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

US Patent:

7973009, Jul 5, 2011

Filed:

Oct 26, 2007

Appl. No.:

11/977845

Inventors:

Joan C. Egrie - Newbury Park CA, US
Steven G. Elliott - Newbury Park CA, US
Jeffrey K. Browne - Camarillo CA, US
Karen C. Sitney - Studio City CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 38/18
C07K 14/505

US Classification:

514 77, 514 11, 530350, 530395

Abstract:

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

US Patent:

7977311, Jul 12, 2011

Filed:

Oct 26, 2007

Appl. No.:

11/977851

Inventors:

Joan C. Egrie - Newbury Park CA, US
Steven G. Elliott - Newbury Park CA, US
Jeffrey K. Browne - Camarillo CA, US
Karen C. Sitney - Studio City CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14/505
A61K 38/16

US Classification:

514 8, 530397

Abstract:

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

US Patent:

8268588, Sep 18, 2012

Filed:

Jun 24, 2011

Appl. No.:

13/168913

Inventors:

Joan C. Egrie - Newbury Park CA, US
Steven G. Elliott - Newbury Park CA, US
Jeffrey K. Browne - Camarillo CA, US
Karen C. Sitney - Studio City CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C12N 15/00
C12N 5/00
C12N 1/00
C07K 14/505

US Classification:

435 691, 435325, 4353201, 530397

Abstract:

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

US Patent:

20080102492, May 1, 2008

Filed:

Oct 26, 2007

Appl. No.:

11/977872

Inventors:

Joan Egrie - Newbury Park CA, US
Steven Elliott - Newbury Park CA, US
Jeffrey Browne - Camarillo CA, US
Karen Sitney - Studio City CA, US

International Classification:

C12P 21/04
C12N 15/00
C12N 15/11
C12N 5/06

US Classification:

435069400, 435320100, 435325000, 435360000, 435366000, 536023510

Abstract:

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

US Patent:

20120322730, Dec 20, 2012

Filed:

Aug 17, 2012

Appl. No.:

13/589026

Inventors:

Joan C. EGRIE - Newbury Park CA, US
Steven G. Elliot - Newbury Park CA, US
Jeffrey K. Browne - Camarillo CA, US
Karen C. Sitney - Studio City CA, US

International Classification:

A61K 38/18
C07K 14/505

US Classification:

514 77, 530380

Abstract:

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

US Patent:

50325191, Jul 16, 1991

Filed:

Oct 24, 1989

Appl. No.:

7/426577

Inventors:

James C. Paulson - Sherman Oaks CA
Karen J. Colley - Los Angeles CA
Beverly Adler - Newbury Park CA
Jeffrey K. Browne - Camarillo CA

Assignee:

The Regents of the Univ. of California - Oakland CA

International Classification:

C12N 1500
C12N 1554
C12N 1563
C12N 1579

US Classification:

435193

Abstract:

A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a r This invention was made with government support under Grant Contract Nos. GM-27904 and GM-11557 awarded by the National Institute of Health. The government has certain rights in this invention. The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the appended bibliography.

US Patent:

55410839, Jul 30, 1996

Filed:

Mar 10, 1994

Appl. No.:

8/209604

Inventors:

James C. Paulson - Del Mar CA
Karen J. Colley - Chicago IL
Beverly Adler - Newbury Park CA
Jeffrey K. Browne - Camarillo CA
Jasminder Weinstein - Westlake Village CA

Assignee:

The Regents of the University of California - Oakland CA
Amgen - Thousand Oaks CA

International Classification:

C12P 1918
C12P 2106
C12P 100
C12N 1552

US Classification:

435 41

Abstract:

A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a retention signal. The resulting altered enzyme becomes soluble and secretable by the cell without losing its catalytic activity. Secretion of the soluble glycosyltransferase by the cell provides for increased production and simplified recovery of glycosyltransferase.